



MANAGEMENT TEAM

Christopher J. Moreau
Chief Executive Officer

Dr. Christopher Bryan, PhD
Vice President Research & Operations

Michael Sadhra, CA
Chief Financial Officer & Director

Dr. Ahmed Khalil, PhD
Chief Medical Officer

BUSINESS ADVISORY BOARD

U.S. Ambassador (Rtd)
Howard Gutman

MEDICAL & SCIENTIFIC ADVISORY BOARD

Dr. Mark Swaim, MD, PhD

Jacky Smith, MB, ChB, FRCP, PhD

Dr. Martin Kolb, MD

BOARD OF DIRECTORS

Christopher J. Moreau, CEO

Raj Attariwala, MD, PhD

Michael Sadhra, CA

David Levine

STOCK INFORMATION

(March 11, 2021)

| | |
|---------------|----------------|
| Shares O/S: | 152 Million |
| Market Cap: | C\$ 50 Million |
| Recent Price: | C\$ 0.30 |

TRADING SYMBOLS

CSE: AGN

OTCQB: AGNPF

XFRA: AGW

INVESTOR INQUIRIES

Christopher J. Moreau, CEO
604.398.4175
chris@algernonpharmaceuticals.com

HEAD OFFICE

Algernon Pharmaceuticals Inc.
Suite 915-700 West Pender St.
Vancouver, BC, Canada, V6C 1G8

CORPORATE PRESENTATION

COMPANY OVERVIEW

Algernon is a drug repurposing company, investigating drugs that have an established safety history for new disease applications, moving them efficiently and safely into new human trials, and seeking new regulatory approvals in billion dollar global disease markets. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life.

Our program specifically investigates compounds that have never been approved in the U.S. or Europe. We protect our lead compounds with method of use, dosing and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.

ALGERNON'S CLINICAL RESEARCH PROGRAMS

STROKE

Algernon has established a clinical research program for the treatment of stroke focused on AP-188 ("N,N-Dimethyltryptamine or DMT"), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.



IDIOPATHIC PULMONARY FIBROSIS (IPF) AND CHRONIC COUGH

Algernon is investigating NP-120 (Ifenprodil) in a proof-of-concept Phase 2 human trial to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough. There are 5 sites in total participating in the study with 3 located in Australia and 2 in New Zealand.

Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of IPF. In addition, Ifenprodil significantly reduced both cough frequency and onset in a guinea pig acute cough model.

COVID-19

The company has been conducting a 150 patient Phase 2b/3 multi-national study of Ifenprodil for COVID-19 and recently announced that the final patient had now completed treatment as well as the required two-week follow up.

The Company announced positive trending interim data for the Phase 2b part of its Phase 2b/3 Ifenprodil COVID-19 Study, on December 15, 2020. The Company is projecting the final data set will be available before the end of February 2021.

